When are they expected to have any revenue? They spent about $95 million dollars in the past 12 months, but I'm not finding any revenue at all. I understand they are a clinical stage development company - but is there light at the end of the tunnel? I know there have been quite a few documents posted in this thread, but is there a plain English (layman's terms) synopsis somewhere of the business case for investing in MNMD?
If you want layman's terms on why you should invest in this company. Look no further than here: Their latest Investor Presentation is here: https://d1io3yog0oux5.cloudfront.ne.../MindMed+Investor+Presentation+-+02.13.24.pdf Very large market for a new drug class and being that they are going into Phase 3 and also just got their MM120 ODT Formulation Patented. I see positivity on the horizon as they get close to commercialization.
Thanks for your reply! I checked it out and it was interesting. It does look like it could be promising. There is certainly a need in the target markets, and they are significant numbers in those markets. One thing I didn't see - maybe I missed it? Is there an estimated timeline of when this could actually move to market and start producing revenue? Assuming successful trials and approvals.
Keep in mind they now have breakthrough designation. This will speed up their Phase 3. Check this video out from Dan Karlin: https://www.hcplive.com/view/daniel...breakthrough-designation-to-mm120-for-anxiety it should help some thoughts surrounding this.
MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer https://www.businesswire.com/news/home/20240729857388/en/ These type of hires are coming in before commercialization. They are bullish on getting FDA approval or there would be no need to hire.
Janus Henderson Group PLC Acquires New Stake in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) https://www.marketbeat.com/instant-alerts/nasdaq-mnmd-sec-filing-2024-08-02/ Janus Henderson Group PLC bought a new position in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 955,678 shares of the company's stock, valued at approximately $8,964,000. Janus Henderson Group PLC owned approximately 1.36% of Mind Medicine (MindMed) at the end of the most recent quarter. Several other hedge funds also recently made changes to their positions in MNMD. Blackstone Inc. acquired a new position in shares of Mind Medicine (MindMed) in the 1st quarter worth approximately $11,749,000. Scotia Capital Inc. acquired a new position in shares of Mind Medicine (MindMed) in the 4th quarter worth approximately $441,000. Moloney Securities Asset Management LLC lifted its holdings in shares of Mind Medicine (MindMed) by 133.0% in the 1st quarter. Moloney Securities Asset Management LLC now owns 161,961 shares of the company's stock worth $1,522,000 after purchasing an additional 92,450 shares during the last quarter. Mitchell Mcleod Pugh & Williams Inc. bought a new stake in shares of Mind Medicine (MindMed) in the 4th quarter worth approximately $73,000. Finally, Sequoia Financial Advisors LLC bought a new stake in shares of Mind Medicine (MindMed) in the 1st quarter worth approximately $168,000. Institutional investors and hedge funds own 27.91% of the company's stock.
180,600 Shares in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Bought by Tidal Investments LLC https://www.marketbeat.com/instant-alerts/nasdaq-mnmd-sec-filing-2024-08-03/ August 3, 2024 Tidal Investments LLC bought a new stake in shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 180,600 shares of the company's stock, valued at approximately $1,698,000. Tidal Investments LLC owned 0.26% of Mind Medicine (MindMed) as of its most recent SEC filing. A number of other institutional investors have also recently modified their holdings of MNMD. SageView Advisory Group LLC acquired a new position in shares of Mind Medicine (MindMed) during the 1st quarter worth about $25,000. Bailard Inc. acquired a new stake in shares of Mind Medicine (MindMed) during the 4th quarter worth approximately $63,000. Mitchell Mcleod Pugh & Williams Inc. purchased a new stake in shares of Mind Medicine (MindMed) during the 4th quarter valued at approximately $73,000. Jump Financial LLC lifted its holdings in Mind Medicine (MindMed) by 8.3% in the fourth quarter. Jump Financial LLC now owns 36,826 shares of the company's stock valued at $135,000 after acquiring an additional 2,826 shares during the last quarter. Finally, Sequoia Financial Advisors LLC acquired a new stake in Mind Medicine (MindMed) during the first quarter worth $168,000. 27.91% of the stock is currently owned by institutional investors and hedge funds.
MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update https://www.businesswire.com/news/home/20240806368517/en/ August 06, 2024 07:00 AM Eastern Daylight Time NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Tuesday, August 13, 2024, at 8:00 a.m. ET to provide a corporate update and review the Company’s results for the second quarter ended June 30, 2024. Listeners can register for the webcast via this link - https://edge.media-server.com/mmc/p/akyzndoh/. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, https://ir.mindmed.co/, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time.
MindMed to Present at Canaccord Genuity’s 44th Annual Growth Conference https://www.businesswire.com/news/home/20240806945771/en/ August 06, 2024 04:01 PM Eastern Daylight Time NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will present at Canaccord Genuity’s 44th Annual Growth Conference: Canaccord Genuity’s 44th Annual Growth Conference Format: Fireside Chat Date and Time: Tuesday, August 13, 2024 at 1:30 PM ET Location: Boston, MA Webcast Link: Canaccord Genuity’s 44th Annual Growth Conference - https://wsw.com/webcast/canaccord98...ps://wsw.com/webcast/canaccord98/mnmd/2458676 Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following the event.
Patents Assigned to Mind Medicine, Inc. - Justia Patents Search https://patents.justia.com/assignee/mind-medicine-inc Spoiler: List of Patents Lyophilized orally disintegrating tablet formulations of d-lysergic acid diethylamide for therapeutic applications Patent number: 12036220 Abstract: A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual. Type: Grant Filed: April 3, 2023 Date of Patent: July 16, 2024 Assignee: Mind Medicine, Inc. Inventors: Peter Mack, Timm Trenktrog, Dustin Melton, Bethany Amber Doty, Jon Schroeder, Lisa Marie Garrett 4-ALKENYL AND 4-ALKYNYL PHENETHYLAMINE DERIVATIVES AND RELATED COMPOUNDS WITH MODIFIED DOM-LIKE ACTION Publication number: 20240174594 Abstract: A composition of a compound represented by FIGS. 1A-1E for use in substance-assisted therapy. A method of changing neurotransmission, by administering a pharmaceutically effective amount of a compound of FIGS. 1A-1E to a mammal, interacting with serotonin 5-HT2A receptors in the mammal, and inducing psychoactive effects. A method of treating a patient having adverse reactions to psychedelics by administering 4-alkenyl and 4-alkynyl phenethylamine derivatives and related compounds as represented in FIGS. 1A-1E to the patient, and avoiding adverse effects present with psychedelics. A method of changing neurotransmission of an individual, by administering 4-alkenyl and 4-alkynyl phenethylamine derivatives and related compounds as represented in FIGS. 1A-1E and changing neurotransmission in the individual. Type: Application Filed: October 24, 2023 Publication date: May 30, 2024 Applicant: Mind Medicine, Inc. Inventors: Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER SYNTHESIS ROUTES TO ACCESS MDMA PRODRUGS BY USING CONTROLLED AND NON-CONTROLLED INTERMEDIATES Publication number: 20240115710 Abstract: A method of synthesizing a pharmacological compound substance by attaching a psychoactive base substance to an amino acid and creating a prodrug with modified pharmacological behavior. A prodrug made by the method. A pharmaceutical composition comprising a prodrug of a psychoactive base substance attached to an amino acid and a pharmaceutically acceptable salt. Type: Application Filed: December 18, 2023 Publication date: April 11, 2024 Applicant: Mind Medicine, Inc. Inventors: Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER Synthesis routes to access MDMA prodrugs by using controlled and non-controlled intermediates Patent number: 11896670 Abstract: A method of synthesizing a pharmacological compound substance by attaching a psychoactive base substance to an amino acid and creating a prodrug with modified pharmacological behavior. A prodrug made by the method. A pharmaceutical composition comprising a prodrug of a psychoactive base substance attached to an amino acid and a pharmaceutically acceptable salt. Type: Grant Filed: August 23, 2022 Date of Patent: February 13, 2024 Assignee: Mind Medicine, Inc. Inventors: Daniel Trachsel, Matthias Emanuel Liechti, Felix Lustenberger METHODS OF MANUFACTURE OF R-MDMA Publication number: 20240010628 Abstract: A method of manufacturing R-MDMA by forming a Grignard reagent from 5-bromobenzodioxole, treating the Grignard reagent with S-propylene oxide to form chirally pure alcohol 1, activating the alcohol as mesylate 2, converting to chirally pure azide 3, reducing the azide to amine 4, protecting the amine with di-tert-butyl dicarbonate, reducing the protected amine 5 to yield R-MDMA free base 6, and treating with an acid to form a salt 7 in >99% e.e. A method of manufacturing S-MDMA by forming a Grignard reagent from 5-bromobenzodioxole, treating the Grignard reagent with R-propylene oxide to form chirally pure alcohol 8, activating the alcohol as mesylate 9, converting to chirally pure azide 10, reducing the azide to amine 11, protecting the amine with di-tert-butyl dicarbonate, reducing the protected amine 12 to yield S-MDMA free base 13, and treating with an acid to form a salt 14 in >99% e.e. Type: Application Filed: June 29, 2023 Publication date: January 11, 2024 Applicant: Mind Medicine, Inc. Inventors: Stephen E. SCHNEIDER, Derek LONDESBROUGH LYSERGIC ACID DERIVATIVES WITH MODIFIED LSD-LIKE ACTION Publication number: 20230414583 Abstract: A composition of a compound represented generically by FIG. 1A for use in substance-assisted therapy. A method of changing neurotransmission, by administering a pharmaceutically effective amount of a compound of FIG. 1A to a mammal, interacting with serotonin 5-HT2A receptors in the mammal, in particular also human beings, and inducing psychoactive effects. A method of treating an individual, by administering a pharmaceutically effective amount of a compound of FIG. 1A to the individual and treating the individual. Type: Application Filed: June 19, 2023 Publication date: December 28, 2023 Applicant: Mind Medicine, Inc. Inventors: Daniel TRACHSEL, Matthias Emanuel Liechti, Felix Lustenberger MDMA PRODRUGS TO ASSIST PSYCHOTHERAPY Publication number: 20230355575 Abstract: A compound including a prodrug having a psychoactive base substance attached to an amino acid. A method of treating an individual, especially in substance-assisted psychotherapy, by administering proMDMA or a proMDMA-like compound to the individual, metabolizing the prodrug, and releasing the MDMA or MDMA-like substance in the individual. A method of reducing anxiety while administering MDMA, by providing a slow release of MDMA or an MDMA-like substance and thereby reducing anxiety in the individual at the onset of administration. A method of personalized medicine, by evaluating an individual and determining if there are characteristics of the individual present that would not be suitable for MDMA treatment and administering proMDMA or a proMDMA-like substance to the individual. A method of reducing abuse of MDMA, by administering proMDMA or a proMDMA-like substance, and providing a delayed and attenuated effect of MDMA or a MDMA-like substance, thereby reducing abuse. Type: Application Filed: May 16, 2023 Publication date: November 9, 2023 Applicant: Mind Medicine, Inc. Inventors: Matthias Emanuel LIECHTI, Felix LUSTENBERGER, Daniel TRACHSEL METHOD OF TITRATING DOSE OF PSYCHEDELICS Publication number: 20230346645 Abstract: A method of dosing a psychedelic that avoids the side effects of hallucinations and perceptual disturbances by administering the psychedelic to an individual in a titrating dosing regimen and reducing side effects of hallucinations and perceptual disturbances. A kit for administering a titrating dosing regimen of a psychedelic, including a pharmaceutically effective amount of the psychedelic in dosage forms separated in packaging according to dose and time of administration in a titrating dosing regimen, and instructions for use. A method of treating an individual with psychedelics, by administering the psychedelic to the individual having a condition or disease in a titrating dosing regimen and reducing side effects of hallucinations and perceptual disturbances during treatment. Type: Application Filed: May 1, 2022 Publication date: November 2, 2023 Applicant: Mind Medicine, Inc. Inventors: Robert Barrow, Daniel R. Karlin MDMA ENANTIOMERS Publication number: 20230310368 Abstract: A composition for use in psychotherapeutic or medical treatment of an R(?) enantiomer of MDMA or MDA. A method of treating an individual for a medical condition (especially autism and social anxiety disorders), by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA and treating the individual. A method of reducing neurotoxicity of MDMA and MDA, by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA to an individual and reducing neurotoxicity of MDMA or MDA while treating the individual. A method of reducing hyperthermia of MDMA and MDA. A method of reducing physical dependence or abuse liability of MDMA and MDA. Type: Application Filed: June 8, 2023 Publication date: October 5, 2023 Applicant: Mind Medicine, Inc. Inventors: Robert BARROW, Daniel R. Karlin, Gennady N. Smagin 18-MC SALT FORMS Publication number: 20230303572 Abstract: A composition including a salt of 18-MC, wherein the salt is chosen from gentisate, hydrobromide, besylate, napadisylate, hydrochloride, sulfate, oxalate, maleate, mesylate, and tosylate. A composition including a polymorph of 18-MC. Type: Application Filed: March 1, 2023 Publication date: September 28, 2023 Applicant: Mind Medicine, Inc. Inventors: Jeanne BONELLE, Daniel Emil LEVY, Ann NEWMAN, Stephen E. SCHNEIDER MOVEMENT DISORDERS Publication number: 20230301985 Abstract: A method of treating movement disorders, by administering an effective amount of a psychedelic to an individual having a movement disorder, and treating the movement disorder. Type: Application Filed: May 16, 2023 Publication date: September 28, 2023 Applicant: Mind Medicine, Inc. Inventors: Robert BARROW, Daniel R. KARLIN, Gennady SMAGIN DESOXYSCALINE DERIVATIVES WITH MODIFIED MESCALINE-LIKE ACTION Publication number: 20230285327 Abstract: A composition of a compound represented by FIG. 1 for use in substance-assisted therapy. A method of changing neurotransmission, by administering a pharmaceutically effective amount of a compound of FIG. 1 to a mammal, interacting with serotonin 5-HT2A receptors in the mammal, in particular also human beings, and inducing psychoactive effects. A method of treating a patient having adverse reactions to psychedelics by administering a desoxyscaline derivative to the patient, and avoiding adverse effects present with psychedelics. A method of changing neurotransmission of an individual, by administering a desoxyscaline derivative, and changing neurotransmission in the individual. Type: Application Filed: May 12, 2023 Publication date: September 14, 2023 Applicant: Mind Medicine, Inc. Inventors: Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS Publication number: 20230285386 Abstract: A solid oral immediate release formulation of LSD, including LSD contained within a dosage form of a capsule, tablet, or orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD as a free base or in a salt form by granulation, including moisture-activated dry granulation or dry blending. A method of treating an individual, by administering a solid oral immediate release formulation of LSD and treating the individual. Type: Application Filed: May 18, 2023 Publication date: September 14, 2023 Applicant: Mind Medicine, Inc. Inventors: Peter MACK, Dustin MELTON, Bethany Amber DOTY, Jon SCHROEDER, James COGHILL, Daniel Emil LEVY FORMULATIONS OF PSILOCIN THAT HAVE ENHANCED STABILITY Publication number: 20230285359 Abstract: A composition of psilocin that is stable including at least one agent or chemical modification that provides enhanced stability. A method making stable psilocin, by providing a formulation of psilocin including at least one agent or chemical modification that provides enhanced stability. A method of treatment of a disease or condition, by administering a composition of psilocin that is stable to an individual and treating the disease or condition. Type: Application Filed: May 31, 2023 Publication date: September 14, 2023 Applicant: Mind Medicine, Inc. Inventors: Robert BARROW, Peter MACK, Stephen SCHNEIDER, Jon SCHROEDER, Gerald S. JONES MDMA PRODRUGS TO ASSIST PSYCHOTHERAPY Publication number: 20230233688 Abstract: A compound including a prodrug having a psychoactive base substance attached to an amino acid. A method of treating an individual, by administering proMDMA, a proMDMA-like compound, or proR(-)MDMA to the individual, metabolizing the prodrug, and releasing the MDMA or MDMA-like substance in the individual. A method of reducing anxiety while administering MDMA, by providing a slow release of MDMA, an MDMA-like substance or R(-)MDMA thereby reducing anxiety in the individual at the onset of administration. A method of personalized medicine, by evaluating an individual and determining if there are characteristics present that would not be suitable for MDMA treatment and administering proMDMA, a proMDMA-like substance, or proR(-)MDMA to the individual. A method of reducing abuse of MDMA, by administering proMDMA, a proMDMA-like substance, or proR(-)MDMA, and providing a delayed and attenuated effect of MDMA or a MDMA-like substance, thereby reducing abuse. Type: Application Filed: March 28, 2023 Publication date: July 27, 2023 Applicant: Mind Medicine, Inc. Inventors: Matthias Emanuel LIECHTI, Felix LUSTENBERGER, Daniel TRACHSEL MDMA ENANTIOMERS Publication number: 20230226019 Abstract: A composition for use in psychotherapeutic or medical treatment of an R(?) enantiomer of MDMA or MDA. A method of treating an individual for a medical condition (especially autism and social anxiety disorders), by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA and treating the individual. A method of reducing neurotoxicity of MDMA and MDA, by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA to an individual and reducing neurotoxicity of MDMA or MDA while treating the individual. A method of reducing hyperthermia of MDMA and MDA. A method of reducing physical dependence or abuse liability of MDMA and MDA. Type: Application Filed: March 20, 2023 Publication date: July 20, 2023 Applicant: Mind Medicine, Inc. Inventors: Robert BARROW, Daniel R. KARLIN MDMA ENANTIOMERS Publication number: 20230226020 Abstract: A composition for use in psychotherapeutic or medical treatment of an R(?) enantiomer of MDMA or MDA. A method of treating an individual for a medical condition (especially autism and social anxiety disorders), by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA and treating the individual. A method of reducing neurotoxicity of MDMA and MDA, by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA to an individual and reducing neurotoxicity of MDMA or MDA while treating the individual. A method of reducing hyperthermia of MDMA and MDA. A method of reducing physical dependence or abuse liability of MDMA and MDA. Type: Application Filed: March 20, 2023 Publication date: July 20, 2023 Applicant: Mind Medicine, Inc. Inventors: Robert BARROW, Daniel R. KARLIN MESCALINE DERIVATIVES WITH MODIFIED ACTION Publication number: 20230227398 Abstract: A composition for use in substance-assisted therapy, wherein: R is hydrogen, methyl, or ethyl, and R? is C1-C5 branched or unbranched alkyl with the alkyl optionally substituted with F1-F5 fluorine substituents up to a fully fluorinated alkyl, C3-C6 cycloalkyl optionally and independently substituted with one or more substituents such as F1-F5 fluorine and/or C1 - C2 alkyl, (C3-C6 cycloalkyl)-C1-C2 branched or unbranched alkyl optionally substituted with one or more substituents such as F1-F5 fluorine and/or C1-C2 alkyl, or C2-C5 branched or unbranched alkenyl with E or Z vinylic, cis or trans allylic, E or Zallylic or other double bond position in relation to the attached ether function, where any of the carbons of the branched or unbranched alkenyl substituent is optionally substituted independently with one or more C1-C2 alkyl, with F1-F5 fluorine or with D1-D5 deuteron substituents. Type: Application Filed: March 27, 2023 Publication date: July 20, 2023 Applicant: Mind Medicine, Inc. Inventors: Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER LYOPHILIZED ORALLY DISINTEGRATING TABLET FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS Publication number: 20230218532 Abstract: A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual. Type: Application Filed: April 3, 2023 Publication date: July 13, 2023 Applicant: Mind Medicine, Inc. Inventors: Peter MACK, Timm TRENKTROG, Dustin MELTON, Bethany Amber DOTY, Jon SCHROEDER, Lisa Marie GARRETT 18-MC FOR TREATMENT OF SUBSTANCE USE DISORDERS Publication number: 20230201217 Abstract: A composition for treating substance use disorders of an effective amount of 18-Methoxycoronaridine salt (18-MC) in a pharmaceutical carrier. A method of treating substance use disorders, by administering an effective amount of 18-Methoxycoronaridine salt (18-MC) in a pharmaceutical carrier to an individual and preventing substance abuse in the individual. A method of preventing addictive behavior in an individual. A method of preventing craving in an individual. A composition of a metabolite of 18-MC salt. A method of treating substance use disorders by administering an effective amount of a metabolite of 18-MC salt in a pharmaceutical carrier to an individual and preventing substance abuse in the individual. A composition having various pharmacokinetic profiles as shown in the Figures. Type: Application Filed: February 24, 2023 Publication date: June 29, 2023 Applicant: Mind Medicine, Inc. Inventors: Scott FREEMAN, Stots B. REELE, Jeanne BONELLE DESOXYSCALINE DERIVATIVES WITH MODIFIED MESCALINE-LIKE ACTION Publication number: 20230150906 Abstract: A composition of a compound represented by FIG. 1 for use in substance-assisted therapy. A method of changing neurotransmission, by administering a pharmaceutically effective amount of a compound of FIG. 1 to a mammal, interacting with serotonin 5-HT2A receptors in the mammal, in particular also human beings, and inducing psychoactive effects. A method of treating a patient having adverse reactions to psychedelics by administering a desoxyscaline derivative to the patient, and avoiding adverse effects present with psychedelics. A method of changing neurotransmission of an individual, by administering a desoxyscaline derivative, and changing neurotransmission in the individual. Type: Application Filed: November 16, 2022 Publication date: May 18, 2023 Applicant: Mind Medicine, Inc. Inventors: Matthias Emanuel LIECHTI, Felix LUSTENBERGER, Daniel TRACHSEL LYOPHILIZED ORALLY DISINTEGRATING TABLET FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS Publication number: 20230122949 Abstract: A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual. Type: Application Filed: December 7, 2022 Publication date: April 20, 2023 Applicant: Mind Medicine, Inc. Inventors: Peter MACK, Timm TRENKTROG, Dustin MELTON, Bethany Amber DOTY, Jon SCHROEDER, Lisa Marie GARRETT IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS Publication number: 20230107398 Abstract: A solid oral immediate release formulation of LSD, including LSD contained within a dosage form of a capsule, tablet, or orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD as a free base or in a salt form by granulation, including moisture-activated dry granulation or dry blending. A method of treating an individual, by administering a solid oral immediate release formulation of LSD and treating the individual. Type: Application Filed: December 7, 2022 Publication date: April 6, 2023 Applicant: Mind Medicine, Inc. Inventors: Peter MACK, Dustin MELTON, Bethany Amber DOTY, Jon SCHROEDER, James COGHILL, Daniel Emil LEVY MESCALINE DERIVATIVES WITH MODIFIED ACTION Publication number: 20230091369 Abstract: A composition for use in substance-assisted therapy, wherein: R is hydrogen, methyl, or ethyl, and R? is C1-C5 branched or unbranched alkyl with the alkyl optionally substituted with F1-F5 fluorine substituents up to a fully fluorinated alkyl, C3-C6 cycloalkyl optionally and independently substituted with one or more substituents such as F1-F5 fluorine and/or C1-C2 alkyl, (C3-C6 cycloalkyl)-C1-C2 branched or unbranched alkyl optionally substituted with one or more substituents such as F1-F5 fluorine and/or C1-C2 alkyl, or C2-C5 branched or unbranched alkenyl with E or Z vinylic, cis or trans allylic, E or Z allylic or other double bond position in relation to the attached ether function, where any of the carbons of the branched or unbranched alkenyl substituent is optionally substituted independently with one or more C1-C2 alkyl, with F1-F5 fluorine or with D1-D5 deuteron substituents. Type: Application Filed: November 28, 2022 Publication date: March 23, 2023 Applicant: Mind Medicine, Inc. Inventors: Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS Publication number: 20230075847 Abstract: A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual. Type: Application Filed: August 17, 2022 Publication date: March 9, 2023 Applicant: Mind Medicine, Inc. Inventors: Peter MACK, Timm TRENKTROG, Dustin MELTON, Bethany Amber DOTY, Jon SCHROEDER, Lisa Marie GARRETT 18-MC for treatment of substance use disorders Patent number: 11596638 Abstract: A composition for treating substance use disorders of an effective amount of 18-Methoxycoronaridine salt (18-MC) in a pharmaceutical carrier. A method of treating substance use disorders, by administering an effective amount of 18-Methoxycoronaridine salt (18-MC) in a pharmaceutical carrier to an individual and preventing substance abuse in the individual. A method of preventing addictive behavior in an individual. A method of preventing craving in an individual. A composition of a metabolite of 18-MC salt. A method of treating substance use disorders by administering an effective amount of a metabolite of 18-MC salt in a pharmaceutical carrier to an individual and preventing substance abuse in the individual. A composition having various pharmacokinetic profiles as shown in the Figures. Type: Grant Filed: October 1, 2020 Date of Patent: March 7, 2023 Assignee: Mind Medicine, Inc Inventors: Scott Freeman, Stots B. Reele, Jeanne Bonelle IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS Publication number: 20230064429 Abstract: A solid oral immediate release formulation of LSD, including LSD contained within a dosage form of a capsule, tablet, or orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD as a free base or in a salt form by granulation, including moisture-activated dry granulation or dry blending. A method of treating an individual, by administering a solid oral immediate release formulation of LSD and treating the individual. Type: Application Filed: August 17, 2022 Publication date: March 2, 2023 Applicant: Mind Medicine, Inc. Inventors: Peter MACK, Dustin MELTON, Bethany Amber DOTY, Jon SCHROEDER, James COGHILL SYNTHESIS ROUTES TO ACCESS MDMA PRODRUGS BY USING CONTROLLED AND NON-CONTROLLED INTERMEDIATES Publication number: 20230066171 Abstract: A method of synthesizing a pharmacological compound substance by attaching a psychoactive base substance to an amino acid and creating a prodrug with modified pharmacological behavior. A prodrug made by the method. A pharmaceutical composition comprising a prodrug of a psychoactive base substance attached to an amino acid and a pharmaceutically acceptable salt. Type: Application Filed: August 23, 2022 Publication date: March 2, 2023 Applicant: Mind Medicine, Inc. Inventors: Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER SYSTEM AND METHOD FOR AUTOMATIC ANALYSIS OF TEXTS IN PSYCHOTHERAPY, COUNSELING, AND OTHER MENTAL HEALTH MANAGEMENT ACTIVITIES Publication number: 20230053429 Abstract: A method of analyzing a patient's mental state, by automatically processing, integrating, and analyzing text-based and audio-based sources from the patient and clinical staff, and generating real-time outcomes and predictions. A system for processing, analyzing, and managing a patient's input including a data pool, model HUB, search service, topic modeling service, mental health related prediction service, and analytics all in electronic communication. A method of analyzing a patient, by processing, analyzing, and managing a patient's and clinical staff's text and audio input, and informing and augmenting diagnostic and prognostic processes, identifying improvement and deterioration of a patient's mental state, and identifying adverse events in psychotherapy, counseling, and other mental health management activities. A system for processing, analyzing, and managing clinical and diagnostic texts, and audio transcripts. Type: Application Filed: August 17, 2022 Publication date: February 23, 2023 Applicant: Mind Medicine, Inc. Inventors: Adam KOLAR, Martin MAJERNIK, Miguel Amavel dos Santos PINHEIRO, Daniel R. KARLIN, Robert BARROW SYSTEM AND METHOD FOR MONITORING A CONSCIOUSNESS-ALTERING THERAPEUTIC SESSION Publication number: 20230000431 Abstract: A system for monitoring patients during a consciousness-altering therapeutic treatment session including a data collection module in electronic communication with network servers for storage of data on non-transitory computer readable media for monitoring a patient's well-being during and after the treatment session. A method of using the system in treating a patient, by continuously, continually, or at the healthcare professionals discretion monitoring the well-being of the patient during a consciousness-altering therapeutic treatment session through one or more wearable devices and a patient mobile device in electronic communication with a facilitator mobile device, and continuously monitoring the well-being of the patient after the treatment session with the wearable device. Type: Application Filed: June 13, 2022 Publication date: January 5, 2023 Applicant: Mind Medicine, Inc. Inventors: Martin MAJERNIK, Daniel R. KARLIN, Robert BARROW, Peter DUBEC 18-MC FOR TREATING OBESITY Publication number: 20220409628 Abstract: A method of treating obesity, by administering an effective amount of a composition chosen from the group consisting of 18-methoxycoronaridine (18-MC), salts thereof, tartrates thereof, solvates thereof, isomers thereof, analogs thereof, homologues thereof, and deuterated forms thereof to an individual and treating obesity. A method of treating binge eating, by administering an effective amount of the composition to an individual and treating binge eating. A method of treating behavioral addictions, by administering an effective amount of the composition to an individual and treating the behavioral addiction. Type: Application Filed: June 8, 2022 Publication date: December 29, 2022 Applicant: Mind Medicine, Inc. Inventors: Robert BARROW, Daniel R. KARLIN System and method for patient monitoring of gastrointestinal function using automated stool classifications Patent number: 11532396 Abstract: A method of data collection of stool data via a mobile device operable to enable monitoring of gastrointestinal function. A related method of long-term monitoring of patient gastrointestinal function, using one or more signal processing tools (e.g. machine learning algorithms) for automatically interpreting patient stool data, including real-time patient-assessments, in order to detect an adverse clinical event from patient stool data. A system for facilitating real-time monitoring the gastrointestinal function, the system comprising: a camera on a mobile device, a user interface that facilitates self-monitoring of stool characteristics, so as to create health-monitoring data; mobile device storage, server storage, and remote storage (with at least one communication link between them) for storing some or all of the health-monitoring data; and a processor for interpreting such health-monitoring data for clinical or other health-monitoring application. Type: Grant Filed: June 12, 2020 Date of Patent: December 20, 2022 Assignee: Mind Medicine, Inc. Inventors: Daniel R Karlin, Peter Dubec, Martin Majernik, Vladimir Boza, Lucia Kvapilova, Dana Rajtarova CONTROLLING EFFECTS AFTER 5HT2A AGONISTS ADMINISTRATION Publication number: 20220395499 Abstract: A composition for treating an individual while reducing acute effects, including effective amounts of a psychedelic drug and a duration shortening agent. A method of treating an individual with a psychedelic drug and reducing or eliminating its acute duration of action, by administering a psychedelic drug to the individual, administering a duration shortening agent to the individual, and shortening and/or reducing and/or eliminating the acute effects of the psychedelic drug. A method of stopping the acute duration of action of a psychedelic drug in an individual, by administering a duration shortening agent to the individual after the individual has taken a psychedelic drug and stopping the acute effects of the psychedelic drug. A method of stopping psychosis due to psychedelic administration, by administering a duration shortening agent to the individual after the individual has taken a psychedelic drug, and stopping psychosis caused by the psychedelic drug. Type: Application Filed: June 6, 2022 Publication date: December 15, 2022 Applicant: Mind Medicine, Inc. Inventors: Daniel R. KARLIN, Robert BARROW FORMULATIONS OF PSILOCIN THAT HAVE ENHANCED STABILITY Publication number: 20220370413 Abstract: A composition of psilocin that is stable including at least one agent or chemical modification that provides enhanced stability. A method making stable psilocin, by providing a formulation of psilocin including at least one agent or chemical modification that provides enhanced stability. A method of treatment of a disease or condition, by administering a composition of psilocin that is stable to an individual and treating the disease or condition. Type: Application Filed: August 8, 2022 Publication date: November 24, 2022 Applicant: Mind Medicine, Inc. Inventors: Robert BARROW, Peter MACK, Stephen SCHNEIDER, Jon SCHROEDER, Gerald S. JONES, JR. PSYCHEDELICS FOR TREATMENT OF PAIN Publication number: 20220362237 Abstract: A method of treating pain, by administering an effective amount of a psychedelic to an individual and treating pain in the individual. A method of treating a pain syndrome, by administering an effective amount of a psychedelic to an individual, and providing a central effect, an effect on depression, and an inflammatory effect. Type: Application Filed: July 29, 2022 Publication date: November 17, 2022 Applicant: Mind Medicine, Inc. Inventors: Robert BARROW, Daniel R KARLIN MDMA ENANTIOMERS Publication number: 20220354822 Abstract: A composition for use in psychotherapeutic or medical treatment of an R(?) enantiomer of MDMA or MDA. A method of treating an individual for a medical condition (especially autism and social anxiety disorders), by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA and treating the individual. A method of reducing neurotoxicity of MDMA and MDA, by administering an effective amount of a composition of an R(?) enantiomer of MDMA or MDA to an individual and reducing neurotoxicity of MDMA or MDA while treating the individual. A method of reducing hyperthermia of MDMA and MDA. A method of reducing physical dependence or abuse liability of MDMA and MDA. Type: Application Filed: May 1, 2022 Publication date: November 10, 2022 Applicant: Mind Medicine, Inc. Inventors: Robert BARROW, Daniel R. KARLIN LIPOSOME DELIVERY OF PSYCHEDELICS Publication number: 20220354862 Abstract: A composition of a psychedelic in a liposome formulation, wherein the composition provides preferential distribution of the psychedelic at the CNS and blood, and reduced distribution at peripheral organs. A method of treating a patient, by administering a composition of a psychedelic in a liposome formulation to the patient, and preferentially distributing the psychedelic at the CNS with a reduced exposure in target peripheral organs (e.g., heart). Type: Application Filed: April 29, 2022 Publication date: November 10, 2022 Applicant: Mind Medicine, Inc. Inventors: Robert BARROW, Gennady N. SMAGIN MOVEMENT DISORDERS Publication number: 20220354831 Abstract: A method of treating movement disorders, by administering an effective amount of a psychedelic to an individual having a movement disorder, and treating the movement disorder. Type: Application Filed: May 1, 2022 Publication date: November 10, 2022 Applicant: Mind Medicine, Inc. Inventors: Robert BARROW, Daniel R. KARLIN LSD SALT CRYSTAL FORMS Publication number: 20220348575 Abstract: Polymorphic forms of lysergic acid diethyl amide (LSD) in crystalline salt forms. A pharmaceutical formulation of polymorphic forms of LSD in crystalline salt forms including pharmaceutically acceptable excipients. Polymorphic forms of LSD free-base. Polymorphic forms of a salt form of LSD. Type: Application Filed: April 26, 2022 Publication date: November 3, 2022 Applicant: Mind Medicine, Inc. Inventors: Daniel Emil LEVY, Stephen E. SCHNEIDER PSYCHEDELICS FOR TREATMENT OF PAIN Publication number: 20220347195 Abstract: A method of treating pain, by administering an effective amount of a psychedelic to an individual and treating pain in the individual. Type: Application Filed: April 29, 2022 Publication date: November 3, 2022 Applicant: Mind Medicine, Inc. Inventors: Robert BARROW, Daniel R KARLIN FORMULATIONS OF PSILOCIN THAT HAVE ENHANCED STABILITY Publication number: 20220280482 Abstract: A composition of psilocin that is stable including at least one agent or chemical modification that provides enhanced stability. A method making stable psilocin, by providing a formulation of psilocin including at least one agent or chemical modification that provides enhanced stability. A method of treatment of a disease or condition, by administering a composition of psilocin that is stable to an individual, and treating the disease or condition. Type: Application Filed: March 4, 2022 Publication date: September 8, 2022 Applicant: Mind Medicine, Inc. Inventors: Robert BARROW, Peter MACK, Stephen SCHNEIDER, Jon SCHROEDER MESCALINE DERIVATIVES WITH MODIFIED ACTION Publication number: 20220267252 Abstract: A composition for use in substance-assisted therapy, wherein: R is hydrogen, methyl, or ethyl, and R? is C1-C5 branched or unbranched alkyl with the alkyl optionally substituted with F1-F5 fluorine substituents up to a fully fluorinated alkyl, C3-C6 cycloalkyl optionally and independently substituted with one or more substituents such as F1-F5 fluorine and/or C1-C2 alkyl, (C3-C6 cycloalkyl)-C1-C2 branched or unbranched alkyl optionally substituted with one or more substituents such as F1-F5 fluorine and/or C1-C2 alkyl, or C2-C5 branched or unbranched alkenyl with E or Z vinylic, cis or trans allylic, E or Z allylic or other double bond position in relation to the attached ether function, where any of the carbons of the branched or unbranched alkenyl substituent is optionally substituted independently with one or more C1-C2 alkyl, with F1-F5 fluorine or with D1-D5 deuteron substituents. Type: Application Filed: February 20, 2022 Publication date: August 25, 2022 Applicant: Mind Medicine, Inc. Inventors: Daniel TRACHSEL, Matthias Emanuel LIECHTI, Felix LUSTENBERGER MDMA PRODRUGS TO ASSIST PSYCHOTHERAPY Publication number: 20220151986 Abstract: A compound including a prodrug having a psychoactive base substance attached to an amino acid. A method of treating an individual, especially in substance-assisted psychotherapy, by administering proMDMA or a proMDMA-like compound to the individual, metabolizing the prodrug, and releasing the MDMA or MDMA-like substance in the individual. A method of reducing anxiety while administering MDMA, by providing a slow release of MDMA or an MDMA-like substance and thereby reducing anxiety in the individual at the onset of administration. A method of personalized medicine, by evaluating an individual and determining if there are characteristics of the individual present that would not be suitable for MDMA treatment and administering proMDMA or a proMDMA-like substance to the individual. A method of reducing abuse of MDMA, by administering proMDMA or a proMDMA-like substance, and providing a delayed and attenuated effect of MDMA or a MDMA-like substance, thereby reducing abuse. Type: Application Filed: November 4, 2021 Publication date: May 19, 2022 Applicant: Mind Medicine, Inc. Inventors: Matthias Emanuel LIECHTI, Felix LUSTENBERGER, Daniel TRACHSEL USE OF 3-METHYLMETHCATHINONE Publication number: 20200360311 Abstract: The present invention relates to methods of drug-assisted psychotherapy with cathinone, particularly methods employing 3-methyl methcathinone (3-MMC). The present invention also relates to kits comprising 3-MMC for use in the treatment of subjects undergoing psychotherapeutic intervention. In particular, methods and kits for drug-assisted psychotherapy with 3-MMC for a variety of disorders and/or conditions, including PTSD, GAD and relationship distress are provided. Type: Application Filed: August 2, 2018 Publication date: November 19, 2020 Applicant: Mind Medicine, Inc. Inventors: Ezekiel GOLAN, Mark HADEN, Rene VAN WETTUM
I usually avoid small cap development stage pharma / biotech investments, but this is an interesting one, as much for the story as the investment. I took a very small position at around $7.50/share.
MindMed - Corporate Presentation - August 2024 https://d1io3yog0oux5.cloudfront.ne...dMed+Investor+Presentation+-++August+2024.pdf It seems like perhaps the recent offering was to help fund a P3 on MM-120 for MDD. If I remember correctly there were some people in the P2b GAD trial with MDD. They had such a good reaction to MM-120 that MindMed is now allowed to skip right to p2b. I don't recall seeing anything about skipping all the way to a P3 for MDD but that looks possible and crazy if so. Lots of good info. Looks like they have final designs for 2 Phase 3 studies with MM-120 for GAD and one more Phase 3 for MDD. FDA must be onboard. HAM-A endpoint just 12 weeks into Phase 3. End of Phase 3 in one year, quite aggressive. Potential drug to market in mid 2026. And they are funded through 2026. Solid..This should pop soon.
MindMed Reports Second Quarter 2024 Financial Results and Business Updates https://finance.yahoo.com/news/mindmed-reports-second-quarter-2024-110000016.html --Completed End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA); on track to initiate Phase 3 clinical program for MM120 orally disintegrating tablet (ODT) in Generalized Anxiety Disorder (GAD) in the second half of 2024-- --Expanding pipeline with MM120 ODT clinical program in Major Depressive Disorder (MDD) with plans to initiate a registrational study in first half of 2025-- --New patent issued by the United States Patent and Trademark Office (USPTO) extends intellectual property protection for MM120 ODT through 2041-- --Company to host a conference call today at 8:00 a.m. EDT--
Psychedelic Stocks: Focus on the Cash Podcast Listen to this... https://open.spotify.com/episode/3nZBsome6WoTEwMhaN8B5y
Mind Medicine (MNMD) Is a Psychedelic Biotechnology Bet https://www.nasdaq.com/articles/small-cap-stocks-mind-medicine-mnmd-psychedelic-biotechnology-bet
Acquisitions of Biotechs - A Discussion concerning the possibility of a MindMed buyout over the next year... Acquisitions of drug companies, particularly in the biotech sector, are common at various stages of clinical development, including during or before Phase 3 trials. The likelihood of MindMed being acquired before concluding Phase 3 trials for its LSD-based drug candidate (MM-120) depends on several factors: Key Considerations: Strategic Fit: Larger pharmaceutical companies often seek to acquire smaller biotechs that have promising drug candidates that fit into their strategic focus areas. Given the rising interest in psychedelics for mental health, MindMed could be attractive to a company looking to expand in this area. Promising Data: MM-120 has shown strong efficacy and safety in Phase 2 trials, which could generate significant interest from potential acquirers. Positive data, especially when coupled with FDA Breakthrough Therapy Designation, increases the perceived value of the drug candidate and the company. Market Trends: The psychedelics space has been heating up with increasing investor interest and regulatory advancements. Companies like Compass Pathways, Cybin, and ATAI Life Sciences have been developing similar treatments. If the sector experiences further consolidation, MindMed could be a target. Financial Strength: Acquisitions often occur when the target company needs additional capital to advance expensive late-stage trials. If MindMed requires significant funding to complete Phase 3 trials, it could be incentivized to consider acquisition offers. (Even though we have a cash runway to 2027 roughly) Examples of Acquisitions During or Before Phase 3: Pharmacyclics and AbbVie: AbbVie acquired Pharmacyclics in 2015 for $21 billion primarily because of its drug Imbruvica, which was in Phase 3 trials at the time. The drug went on to become a blockbuster treatment for B-cell cancers. Receptos and Celgene: Celgene acquired Receptos in 2015 for $7.2 billion while Receptos was in late-stage development of ozanimod, a treatment for multiple sclerosis and ulcerative colitis. This acquisition happened before Receptos completed its Phase 3 trials. Arena Pharmaceuticals and Pfizer: Pfizer acquired Arena Pharmaceuticals in 2021 for $6.7 billion while Arena was in late-stage clinical development of its drug candidate for inflammatory bowel disease (IBD). MindMed's Acquisition Odds: High Potential: Given the Breakthrough Therapy Designation and growing focus on psychedelic treatments, MindMed has a high potential for acquisition if the company delivers strong clinical results. Timing: Acquisitions often happen before or during Phase 3 trials when the risk is lower but before the full commercial value is realized. If MM-120 shows promise and aligns with a larger company’s strategic objectives, an acquisition before Phase 3 completion is a plausible outcome. Overall, the odds of MindMed being acquired before Phase 3 trials are concluded are realistic, especially if they continue to demonstrate positive clinical data and if larger pharma companies are eager to enter the psychedelic therapeutics space. The value of a drug candidate for Generalized Anxiety Disorder (GAD) and/or Major Depressive Disorder (MDD) to a large pharmaceutical company can vary significantly depending on several factors, including the drug's efficacy, safety profile, market potential, and the competitive landscape. Market Size for GAD and MDD GAD Market: The global market for anxiety disorder treatments is projected to reach over $7 billion by 2027, driven by increasing prevalence and demand for more effective therapies. MDD Market: The market for major depressive disorder treatments is much larger, projected to exceed $16 billion by 2030. Depression is one of the most common mental health disorders globally, creating significant demand for innovative treatments. Potential Valuation Blockbuster Potential: A drug candidate that successfully treats either GAD or MDD with a novel mechanism of action, particularly if it offers improvements over existing treatments, could be worth billions to a large pharmaceutical company. Drugs that achieve annual sales exceeding $1 billion are considered "blockbusters," and large pharma companies often pay premium prices to acquire such assets. Examples Spravato (Esketamine): Developed by Janssen, this nasal spray for treatment-resistant depression is expected to generate over $1 billion in annual sales, making it a blockbuster drug. If a novel GAD or MDD treatment demonstrated similar promise, it could achieve a comparable valuation. Xanax (Alprazolam): While it is off-patent, Xanax was a top-selling drug for anxiety and panic disorders, generating billions in sales at its peak. A novel GAD treatment could capture similar market share. Acquisition Prices Acquisitions of biotech companies with promising psychiatric drug candidates have commanded significant valuations, often in the billions. Factors Impacting Valuation Phase of Development: The further along the drug is in clinical trials, the higher the valuation. Drugs in Phase 2 or 3 with positive data tend to attract higher acquisition offers because they present less risk. Breakthrough Designation: An FDA Breakthrough Therapy Designation (BTD), like MindMed's MM-120, adds significant value, as it accelerates development timelines and improves the likelihood of approval. Competitive Landscape: If there are few alternatives or if the drug offers a novel approach (e.g., fewer side effects, faster onset of action), it could command a premium. Estimated Valuation Range: Mid-Stage (Phase 2): A promising drug candidate for GAD or MDD in Phase 2 trials could be valued in the range of **$500 million to $2 billion** based on preliminary efficacy and market. Late-Stage (Phase 3 or Beyond): If the drug is in Phase 3 trials or approaching regulatory approval, its valuation could rise to **$2 billion to $5 billion or more**, particularly if it shows strong clinical results and addresses unmet needs in a large market. There are approx 82.4M Outstanding shares after last raise. If we were bought out in phase 3 here are the prices per share with valuation tiers. 1B = 12.13/share 2B = 24.27/share 3B = 36.40/share 4B = 48.54/share 5B = 60.67/share 6B = 72.81/share 7B = 84.94/share 8B = 97.08/share 9B = 109.21/share 10B = 121.34/share My opinion is MindMed is valued somewhere between 4-6B as we approach FDA approval or if they are made an offer Barrow and team cannot refuse. They already claim they are offering employee stock options. The writing of success is on the walls. We might be quiet for a little bit but I'm excited. The only other comparison that I really don't like making but will for the sake of this discussion is GWPH... GW Pharmaceuticals (GWPH) was acquired by Jazz Pharmaceuticals in February 2021 for $7.2 billion. This acquisition was primarily driven by GW Pharmaceuticals' success with Epidiolex, a cannabis-derived drug used to treat rare forms of epilepsy, including Dravet syndrome and Lennox-Gastaut syndrome. Epidiolex was the first FDA-approved cannabidiol (CBD) medication and generated significant revenue, which made GWPH an attractive acquisition target. The deal included a combination of cash and stock, with Jazz Pharmaceuticals paying $220 per share, representing a substantial premium over GWPH's market price at the time. This acquisition highlighted the growing interest in cannabinoid-based therapies and the premium that pharmaceutical companies are willing to pay for successful, market-leading drugs. The acquisition of GW Pharmaceuticals by Jazz Pharmaceuticals occurred after the commercialization of its flagship product, Epidiolex. Timeline: Epidiolex was approved by the FDA in June 2018 for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, making it the first FDA-approved CBD-based drug. Commercialization: Epidiolex was launched shortly after FDA approval and began generating significant revenue. Acquisition: Jazz Pharmaceuticals announced its acquisition of GW Pharmaceuticals in February 2021, nearly three years after Epidiolex was already on the market. By the time of the acquisition, Epidiolex had proven its commercial success, which significantly contributed to GW Pharmaceuticals' high valuation. The deal was driven by Epidiolex's established market position and revenue potential rather than by pipeline drugs still in clinical trials. By this example we could be worth 10B+ if MindMed brings MM120 to market themselves. The floor is yours...
Evaluating passive physiological data collection during Spravato treatment https://www.frontiersin.org/journal...=EMLX&utm_campaign=PRD_FEOPS_20170000_ARTICLE \r\nTodd M. Solomon Todd M. Solomon1*Matus HajdukMatus Hajduk1Martin MajernikMartin Majernik1Jamileh JemisonJamileh Jemison1Alexander DeschampsAlexander Deschamps1Jenna ScogginsJenna Scoggins1Adam KolarAdam Kolar1Miguel Amvel PinheiroMiguel Amável Pinheiro1Peter DubecPeter Dubec1Ondrej SkalaOndrej Skala1Owen MuirOwen Muir2Amanda TinkelmanAmanda Tinkelman2Daniel R. Karlin,Daniel R. Karlin1,3Robert Barrow\r\nRobert Barrow1 1Global Clinical Development, Mind Medicine (MindMed), Inc., New York, NY, United States 2Brooklyn Minds Psychiatry & Curated Mental Health, New York, NY, United States 3Department of Psychiatry, Tufts University School of Medicine, Boston, MA, United States --- Spravato and other consciousness-altering treatments show significant promise in treating a variety of mental health disorders, but using these substances as effective treatments comes with a significant patient monitoring burden. Passive monitoring could help alleviate this burden, potentially reducing the cost and increasing the accessibility of these treatments. We conducted the first study of the MindMed Session Monitoring System (MSMS), a passive monitoring system designed for consciousness-altering treatment sessions. Results indicated that the system reliably collected data during clinical treatment sessions with Spravato, with high rates of session coverage and low rates of data corruption. Additionally, user acceptability data indicated that participants and HCPs experienced a low burden while using the system and that it did not interfere with the therapeutic effects of a Spravato treatment session. More research and development are needed to fully explore the potential of passive monitoring systems such as MSMS.
MNMD down today to its lowest level since March. Could well be a buying opportunity for those interested. I suspect this may be a reaction to the Lykos Therapeutics FDA rejection of their MDMA-candidate treatment, but MNMD situation is much different, and much more positive, overall, it seems to me.
Wont stay at these levels for long. I suspect the same about Lycos. They are in lock step with FDA and have the right team to pull this off. Big opportunity here. Going to be interesting to look back a year from now on this one.
MindMed has Institutional Ownership of 51.01% which is the highest in all companies in this space and is 14.91% of the PSIL ETF which is the highest holding with the next one coming in at 9.59%
